Cargando…
P784: CYCLOSPORINE WITH THROMBOPOIETIN RECEPTOR AGONIST IN THE TREATMENT OF APLASTIC ANEMIA WITH OR WITHOUT ANTI-THYMOCYTE IMMUNOGLOBULIN:A MULTICENTER REAL WORLD RETROSPECTIVE STUDY
Autores principales: | Chen, Miao, Han, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430684/ http://dx.doi.org/10.1097/01.HS9.0000970040.32760.b3 |
Ejemplares similares
-
An investigation of long-term outcome of rabbit anti-thymocyte globulin and cyclosporine therapy for pediatric severe aplastic anemia
por: Chang, Lixian, et al.
Publicado: (2023) -
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan
por: Imada, Kazunori, et al.
Publicado: (2020) -
Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
por: Wan, Ziqi, et al.
Publicado: (2023) -
Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
por: Wan, Ziqi, et al.
Publicado: (2023) -
Effective treatment of aplastic anemia secondary to chemoradiotherapy using cyclosporine A
por: Ruan, Jing, et al.
Publicado: (2021)